United Kingdom Veterinary Healthcare Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 1.75 Billion |
| Market Size (2029) | USD 2.45 Billion |
| CAGR (2024 - 2029) | 6.94 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
United Kingdom Veterinary Healthcare Market Analysis
The United Kingdom Veterinary Healthcare Market size is estimated at USD 1.75 billion in 2024, and is expected to reach USD 2.45 billion by 2029, growing at a CAGR of 6.94% during the forecast period (2024-2029).
The major factors driving the market's growth include the rise in pet adoptions, novel product developments in the veterinary industry, and increasing initiatives by governments and animal welfare associations in the region.
For instance, in August 2023, the Biotechnology and Biological Sciences Research Council (BBSRC) and the Department for Environment, Food and Rural Affairs (Defra) allocated GBP 9 million (USD 11.51 million) in funding for the second phase of the pioneering endemic livestock disease initiative. Similarly, in May 2023, the Biotechnology and Biological Sciences Research Council (BBSRC) received funding to mechanistically understand host-pathogen interactions in farmed animals and tackle veterinary antimicrobial resistance (Vet-AMR). The project comprised a UK component funded by BBSRC and an Indian component funded by DBT, with a total of GBP 5 million (USD 6.39 million) allocated from BBSRC and matched resources from DBT for successful Indian applicants.
Additionally, increasing product launches in the United Kingdom's veterinary industry may significantly contribute to market growth. For instance, in October 2023, MSD launched Bovilis Nasalgen-C, an intranasal live bovine coronavirus (BCoV) vaccine, in the United Kingdom. Bovilis Nasalgen-C is an immunization product designed for neonatal calves to mitigate clinical symptoms of upper respiratory tract disease and reduce nasal viral shedding caused by BCoV infection. Similarly, in April 2022, Vetoquinol introduced Felpreva to the UK market. Felpreva is a quarterly feline spot-on parasiticide targeting endoparasites and ectoparasites. It offers a solution to decrease the frequency of treatments and minimize stressful interactions between pet owners and their cats.
In conclusion, the factors mentioned above, such as increasing investments and product launches, are expected to boost the growth of the UK veterinary healthcare market during the forecast period. However, counterfeit medicines and the increasing cost of animal testing and veterinary services are expected to hinder the market's growth during the study period.
United Kingdom Veterinary Healthcare Market Trends
Dogs and Cats Segment is Expected to Witness Significant Growth During the Forecast Period
- The growing population of dogs and the increasing number of pet owners are boosting the UK veterinary healthcare market. This trend is driven by the rising awareness of pet health and wellness, which leads to higher spending on veterinary products such as medications and preventive care.
- Pet owners are becoming increasingly committed to their dogs and cat's health and welfare, which is expected to grow the segment. For instance, according to a report published by the FEDIAF, the European Pet Food Industry in July 2023, in the United Kingdom, there were over 13 million dogs in the country in 2022. Over 34% of the households owned at least one dog, and over 28% owned a cat.
- The advancements in technology, increasing product approvals, partnerships, and collaborations by key players are fueling the market's growth. For instance, in November 2023, Antech inaugurated a new laboratory in Warwick, United Kingdom. This initiative marks a significant expansion of Antech's existing UK laboratory network, which presently encompasses the Southfields Veterinary Specialists Diagnostic Laboratory and the Dick White Referrals Diagnostic Laboratory.
- In conclusion, the UK veterinary medicine market's growth is fueled by the increasing importance of cats and dogs in households, advancements in veterinary medicine, and expanding pet healthcare services and products.
Vaccines Segment is Expected to Witness Considerable Growth During the Forecast Period
- Vaccines consist of inactivated or attenuated viruses, bacteria, or other pathogens that are rendered non-pathogenic, thereby enhancing immunity. Advanced vaccines now include genetically engineered elements derived from these pathogens. This segment is anticipated to be propelled by innovations in vaccine technology, heightened awareness of animal health, increased investments from government entities and organizations, and the rising incidence of infectious zoonotic diseases among companion animals.
- Key players in the country are focused on developing and launching new products to meet the growing demand for veterinary solutions. For instance, in October 2023, Zoetis unveiled CircoMax in Europe, a cutting-edge vaccine designed to combat Porcine Circovirus type 2 (PCV2). This innovative vaccine, encompassing genotypes a and b, offers an extensive shield against the PCV2 menace. CircoMax has proven its efficacy in safeguarding against PCV2a, PCV2b, and PCV2d strains.
- Similarly, in March 2023, the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), the Foreign, Commonwealth, and Development Office (FCDO), and the Bill & Melinda Gates Foundation have jointly invested over GBP 40 million (USD 50.89 million) to establish a new center at the Pirbright Institute. This initiative aims to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases, promoting a One Health approach to enhance the health and well-being of both animals and humans.
- Consequently, such product launches by key industry players in the United Kingdom are expected to generate new market opportunities and drive segment growth over the forecast period.
- Moreover, rising growth strategies such as collaboration and partnership are helping boost the market's growth. For instance, in October 2023, the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) at the Pirbright Institute signed a memorandum of understanding (MOU) with the University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization (VIDO). The MOU allows for expanded collaborations and training around vaccine manufacturing to drive innovations for animal health.
- In conclusion, the UK veterinary vaccine market is poised for robust growth, driven by technological advancements and key players' increasing growth strategies.
United Kingdom Veterinary Healthcare Industry Overview
The UK veterinary healthcare market is moderately competitive, with the presence of several global and international market players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are launching new products, while others are distributing the products. Some of the companies that are currently dominating the market are Bayer AG, Boehringer Ingelheim, MSD Animal Health, Virbac Corporation, and Ceva Santé Animale.
United Kingdom Veterinary Healthcare Market Leaders
-
Boehringer Ingelheim
-
MSD Animal Health
-
Virbac Corporation
-
Ceva Santé Animale
-
Elanco
*Disclaimer: Major Players sorted in no particular order
United Kingdom Veterinary Healthcare Market News
- April 2024: Antech launched a new, rapid canine cancer test for use in practice in the United Kingdom. The Nu.Q Canine Cancer Test is a technology that measures circulating nucleosomes in order to enable earlier cancer detection in some of the most common types of canine cancers.
- February 2024: ECO Animal Health Group PLC informed that the ECOVAXXIN trademark was approved by the European Union. The registration for ECOVAXXIN provides trademark branding for a family of vaccine products. ECOVAXXIN is a master trademark and will protect all ECO's forthcoming vaccine products. Starting in 2025, the company plans to market its vaccine products in multiple jurisdictions, with multiple planned launches over the next ten-year period.
UK Veterinary Healthcare Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advanced Technology Leading to Innovations in Animal Healthcare
4.2.2 Increasing Pet Ownership
4.2.3 Increasing Productivity at the Risk of Emerging Zoonosis
4.3 Market Restraints
4.3.1 Use of Counterfeit Medicines
4.3.2 Increasing Pet Care Costs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
5.1 By Product
5.1.1 Therapeutics
5.1.1.1 Vaccines
5.1.1.2 Parasiticides
5.1.1.3 Anti-infectives
5.1.1.4 Medical Feed Additives
5.1.1.5 Other Therapeutics
5.1.2 Diagnostics
5.1.2.1 Immunodiagnostic Tests
5.1.2.2 Molecular Diagnostics
5.1.2.3 Diagnostic Imaging
5.1.2.4 Clinical Chemistry
5.1.2.5 Other Diagnostics
5.2 By Animal Type
5.2.1 Dogs and Cats
5.2.2 Horses
5.2.3 Ruminants
5.2.4 Swine
5.2.5 Poultry
5.2.6 Other Animal Types
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Boehringer Ingelheim International GmbH
6.1.2 Ceva Animal Health Inc.
6.1.3 Covetrus Inc.
6.1.4 ECO Animal Health Ltd
6.1.5 Elanco
6.1.6 KRKA UK Ltd
6.1.7 MSD Animal Health
6.1.8 TVM UK
6.1.9 Vetoquinol UK Limited
6.1.10 Virbac Corporation
6.1.11 Zoetis Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
United Kingdom Veterinary Healthcare Industry Segmentation
As per the report's scope, veterinary healthcare can be defined as the science associated with diagnosing, treating, and preventing animal diseases. The increasing importance of the production of livestock animals is generating growth in the veterinary healthcare market. The UK veterinary healthcare market is segmented by product and animal type. The product segment is further segmented into therapeutics and diagnostics. The therapeutics segment is further segmented into vaccines, parasiticides, anti-infectives, medical feed additives, and other therapeutics, while the diagnostic segment is divided into immunodiagnostic tests, molecular diagnostics, diagnostic imaging, clinical chemistry, and other diagnostics. The animal type segment is further divided into dogs and cats, horses, ruminants, swine, poultry, and other animals. The report offers the value (USD) for the above segments.
| By Product | |||||||
| |||||||
|
| By Animal Type | |
| Dogs and Cats | |
| Horses | |
| Ruminants | |
| Swine | |
| Poultry | |
| Other Animal Types |
UK Veterinary Healthcare Market Research FAQs
How big is the United Kingdom Veterinary Healthcare Market?
The United Kingdom Veterinary Healthcare Market size is expected to reach USD 1.75 billion in 2024 and grow at a CAGR of 6.94% to reach USD 2.45 billion by 2029.
What is the current United Kingdom Veterinary Healthcare Market size?
In 2024, the United Kingdom Veterinary Healthcare Market size is expected to reach USD 1.75 billion.
Who are the key players in United Kingdom Veterinary Healthcare Market?
Boehringer Ingelheim, MSD Animal Health, Virbac Corporation, Ceva Santé Animale and Elanco are the major companies operating in the United Kingdom Veterinary Healthcare Market.
What years does this United Kingdom Veterinary Healthcare Market cover, and what was the market size in 2023?
In 2023, the United Kingdom Veterinary Healthcare Market size was estimated at USD 1.63 billion. The report covers the United Kingdom Veterinary Healthcare Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the United Kingdom Veterinary Healthcare Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the factors driving the Veterinary Healthcare Market in UK?
The factors driving the Veterinary Healthcare Market in UK are a) Government regulations on animal welfare and disease control can indirectly stimulate the veterinary healthcare market b) Increased pet owner knowledge about pet health and preventive care can drive demand for veterinary services and products
UK Veterinary Healthcare Industry Report
The veterinary healthcare market in the United Kingdom, driven by advanced technology and increasing pet ownership, is showing promising growth trajectories, particularly in the molecular diagnostics and vaccines segments. Enhanced by technologies like PCR and microarrays, the molecular diagnostics segment is gaining momentum due to its high sensitivity and fast results, alongside innovative product launches from leading animal health companies in the UK. Meanwhile, the vaccines segment is projected to witness substantial growth, powered by continuous innovations and the development of genetically engineered vaccines that boost animal immunity. Significant investments are being made to enhance animal health and prevent diseases among companion animals, further bolstering market growth. For detailed statistics on market share, size, and revenue growth, along with a forecast outlook, refer to the latest Mordor Intelligence™ industry reports on the UK veterinary healthcare sector. Get a sample of this industry analysis as a free report PDF download.
